Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A new single-dose hepatitis B vaccine versus a conventional vaccine in patients with end-stage renal disease

Nature Clinical Practice Nephrology volume 2, pages 356–357 (2006)Cite this article

boxed-textTong NKC et al. (2005) Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 68: 2298–2303

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Fabrizi F and Martin P (2001) Hepatitis B vaccine and dialysis: current issues. Int J Artif Organs 24: 683–694

    CAS  Article  Google Scholar 

  2. Centers for Disease Control and Prevention (2001) Recommendations for preventing transmission of infectious diseases among chronic hemodialysis patients. MMWR Recomm Rep 50: 1–43

  3. Verkade MA et al. (2004) Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int 66: 614–621

    CAS  Article  Google Scholar 

  4. Roozbeh J et al. (2005) Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J 51: 242–245

    CAS  Article  Google Scholar 

  5. Oddone EZ et al. (1993) A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients. Health Serv Res 28: 97–121

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Affiliations

  1. Staff Nephrologist in the Division of Nephrology at Maggiore Hospital, Policlinico IRCCS, Milan, Italy

    Fabrizio Fabrizi

  2. Professor of Medicine in the Division of Liver Diseases at Mount Sinai School of Medicine, New York, NY, USA

    Paul Martin

Authors
  1. Fabrizio Fabrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabrizio Fabrizi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fabrizi, F., Martin, P. A new single-dose hepatitis B vaccine versus a conventional vaccine in patients with end-stage renal disease. Nat Rev Nephrol 2, 356–357 (2006). https://doi.org/10.1038/ncpneph0215

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0215

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing